Advancements in nano-enabled therapeutics for neuroHIV management.
This viewpoint is a global call to promote fundamental and applied research aiming toward designing smart nanocarriers of desired properties, novel noninvasive strategies to open the blood-brain barrier (BBB), delivery/release of single/multiple therapeutic agents across the BBB to eradicate neurohuman immunodeficiency virus (HIV), strategies for on-demand site-specific release of antiretroviral therapy, developing novel nanoformulations capable to recognize and eradicate latently infected HIV reservoirs, and developing novel smart analytical diagnostic tools to detect and monitor HIV infection. Thus, investigation of novel nanoformulations, methodologies for site-specific delivery/release, analytical methods, and diagnostic tools would be of high significance to eradicate and monitor neuroacquired immunodeficiency syndrome. Overall, these developments will certainly help to develop personalized nanomedicines to cure HIV and to develop smart HIV-monitoring analytical systems for disease management.
Center for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Ajeet
A
Kaushik
Center for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Rahul Dev
RD
Jayant
Center for Personalized NanoMedicine, Institute of NeuroImmune Pharmacology, Department of Immunology, Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.
Madhavan
M
Nair
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000187:drug effects; D019468:Disease Management; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems / Q000379:methods*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D050997:Nanomedicine / Q000379:methods*; D019965:Neurocognitive Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D019380:Anti-HIV Agents; D004337:Drug Carriers
HIV disease management; nanotherapeutics; personalized nanomedicine; smart monitoring analytical systems